Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.

NCT01525836 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT01525836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01525836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.
Lead sponsor
Shandong University
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
June 30, 2014
Enrollment
123 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura, purpura